Identification of chemicals that enhance expression of myoblast growth factor Dp71ab

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K07875
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52050:Embryonic medicine and pediatrics-related
• Research Institution: Kobe Tokiwa University (2023); Kobe Gakuin University (2021)
• Principal Investigator: MATSUO Masafumi 神戸常盤大学, 保健科学部, 特命教授 (10157266)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: デュシェンヌ型筋ジストロフィー / Dp71ab / ジストロフィン / 筋芽細胞 / 化合物

Outline of Final Research Achievements

Duchenne muscular dystrophy (DMD) is a progressive muscular atrophy characterized by a decrease in muscle cells due to myoblast depletion. Establishment of a method for myoblast proliferation is an urgent issue in the treatment of DMD. We were the first in the world to demonstrate that Dp71ab, an isoform of Dp71, is a myoblast growth factor. In this study, we succeeded in developing a compound (Dp71abxx) that expresses Dp71ab and further demonstrated that Dp71abxx promotes proliferation of human myoblasts. It is greatly expected that an innovative DMD treatment using Dp71abxx will be established in the future.

Free Research Field

医学

Academic Significance and Societal Importance of the Research Achievements

ヒト筋芽細胞の増殖を促進する化合物Dp71abxxを世界に先駆けて開発した。今後、筋芽細胞の移植治療のための体外での筋芽細胞を増殖あるいはDMD患者体内での筋芽細胞増殖治療などにDp71abxxが応用されることが大きく期待される。